Physician profile
Eric M Reiners
NPI 1396057618
$4,453.15
in general payments reported to CMS, 2019-2025
20 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $440 · 2021: $842 · 2022: $1,071 · 2023: $555 · 2024: $597 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,996.91 | 2019-2024 | Xarelto |
| Pfizer INC. | $507.08 | 2019-2025 | |
| Abbvie INC. | $391.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $270.41 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $241.44 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.64 | 2023-2025 | Xifaxan |
| Inari Medical, INC. | $174.48 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alexion Pharmaceuticals, INC. | $151.51 | 2023-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $135.69 | 2019 | |
| Merck Sharp & Dohme LLC | $100.46 | 2022-2024 | Dificid, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.08 | 2022-2025 | Jardiance, Spiriva Respimat |
| Portola Pharmaceuticals, LLC | $40.15 | 2019 | |
| Chiesi USA, INC. | $36.20 | 2024 | Cleviprex |
| Stryker Corporation | $30.48 | 2025 | Artix Mt |
| Amgen INC. | $21.10 | 2024 | Evenity, Prolia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $19.30 | 2024 | |
| Mylan Specialty L.P. | $17.85 | 2024 | Yupelri |
| Medtronic, INC. | $16.37 | 2023 | Intellis Adaptivestim |
| Avanir Pharmaceuticals, INC. | $15.66 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.62 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Reiners listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.